Cosponsor
Sign in

HR 1476 · in committee · significant

PLASMA Act

What this bill does

  • This bill gradually reduces Medicare drug discounts for plasma-derived medicines over several years.
  • It affects Medicare beneficiaries who use plasma-derived products and the manufacturers who make them.
  • Discounts phase in starting at 1% in 2026, reaching full rates by 2030-2032.

Generated by claude-haiku-4-5

Community Threads

Started by Cosponsor

  1. 01

    How might the gradual reduction in Medicare drug discounts for plasma products affect out-of-pocket costs for seniors who depend on these medicines?

  2. 02

    What evidence supports the claim that reducing discounts will incentivize manufacturers to increase plasma-derived medicine production or innovation?

  3. 03

    Which groups would benefit most from this policy change, and which might face financial or access challenges as discounts phase out?

Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.

Sponsor · R-NC-9

Richard Hudson

Citizen cosponsors

0

In Congress

5/ 435

House Reps cosponsoring

Introduced 2025-02-21

Joining the bill

Legislative timeline

  1. 2025-02-21 · house · IntroReferral

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  2. 2025-02-21 · house · IntroReferral

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  3. 2025-02-21 · IntroReferral

    Introduced in House

  4. 2025-02-21 · IntroReferral

    Introduced in House

Congress.gov ↗

Citizen comments

Sign in to comment on this bill.

No comments yet — be the first.